Substance use disorder comorbidity in major depressive disorder: a confirmatory analysis of the STAR*D cohort.
The demographics and clinical features were compared between those with (29.4%) and without concurrent substance use disorder (SUD) in 2541 outpatients with major depression (MDD) enrolled in the Sequenced Treatment Alternatives to Relieve Depression study. Compared to those without SUD, MDD patients with concurrent SUD were more likely to be younger, male, divorced or never married, and at greater current suicide risk, and have an earlier age of onset of depression, greater depressive symptomatology, more previous suicide attempts, more frequent concurrent anxiety disorders, and greater functional impairment (p = 0.048 to <0.0001). They were also less likely to be Hispanic and endorse general medical comorbidities (p = 0.006 and 0.002, respectively).
Davis
Lori L
LL
VA Medical Center, Tuscaloosa, AL 35404, USA. lori.davis@med.va.gov
Frazier
Elizabeth
E
Husain
Mustafa M
MM
Warden
Diane
D
Trivedi
Madhukar
M
Fava
Maurizio
M
Cassano
Paolo
P
McGrath
Patrick J
PJ
Balasubramani
G K
GK
Wisniewski
Stephen R
SR
Rush
A John
AJ
D000293:Adolescent; D000328:Adult; D000368:Aged; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use; D001008:Anxiety Disorders / Q000175:diagnosis / Q000453:epidemiology / Q000523:psychology / Q000534:rehabilitation; D016642:Bupropion / Q000627:therapeutic use; D015283:Citalopram / Q000627:therapeutic use; D015928:Cognitive Behavioral Therapy; D015331:Cohort Studies; D003131:Combined Modality Therapy; D015897:Comorbidity; D003511:Cyclohexanols / Q000627:therapeutic use; D003865:Major Depressive Disorder / Q000175:diagnosis / Q000453:epidemiology* / Q000523:psychology / Q000534:rehabilitation; D017831:Diagnosis, Dual (Psychiatry); D005163:Factor Analysis, Statistical; D005260:Female; D006801:Humans; D008297:Male; D010555:Personality Inventory; D019233:Retreatment; D012307:Risk Factors; D020280:Sertraline / Q000627:therapeutic use; D019966:Substance-Related Disorders / Q000175:diagnosis / Q000453:epidemiology* / Q000523:psychology / Q000534:rehabilitation; D013405:Suicide / Q000523:psychology; D000069470:Venlafaxine Hydrochloride; D000092864:Suicide Prevention
D018687:Antidepressive Agents, Second-Generation; D003511:Cyclohexanols; D016642:Bupropion; D015283:Citalopram; D000069470:Venlafaxine Hydrochloride; D020280:Sertraline